Preclinical studies have shown that blocking CD36, especially in combination with FASN inhibitors and anti-PD-1 therapy, produces synergistic anti-tumor effects, suggesting a promising combinatorial treatment strategy (Drury et al., 2020). Here, FASN is linked to neoplasm.